key: cord-0868728-fty4w15c
authors: Sobolewski, Kristine A.; Smoke, Steven M.; Brophy, Alison; Vassallo, Andrew V.; Chen, Brandon; Hilden, Patrick; Patterson, Rebecca; Pittiglio, Marina; Raja, Karan; Handler, Eric; Freer, Christopher
title: Real‐world evaluation of the impact of two anti‐SARS‐CoV‐2 monoclonal antibody regimens on COVID‐19 hospitalizations in older adults
date: 2022-03-03
journal: J Med Virol
DOI: 10.1002/jmv.27668
sha: f0417c550b7a5a52788c238883172ab80388ab53
doc_id: 868728
cord_uid: fty4w15c

Evidence from clinical trials suggest anti‐SARS‐CoV‐2 monoclonal antibodies (mABs) may reduce coronavirus disease 2019 (COVID‐19)‐related hospitalizations. The purpose of this study was to assess the real‐world impact of mAB administration on COVID‐19 hospitalization among patients 65 years or older. This was a retrospective, propensity‐matched cohort study that included patients aged 65 years and older who presented to the emergency department (ED) within 10 days of symptom onset of mild to moderate COVID‐19 infection. Outcomes were compared between those who did and did not receive mAB therapy. The primary endpoint was the rate of hospitalization for COVID‐19 within 30 days of index ED visit. A total of 137 patients receiving mABs were matched to 137 controls. Hospitalization occurred in 2.9% of mAB‐treated patients compared to 14.6% of patients of the standard of care (SOC) arm (odds ratio: 0.20 [95% CI: 0.07–0.59]). There were zero intubations and zero deaths compared to 3 (2.2%) and 2 (1.5%) in the SOC group. Among the 223 patients receiving mAB in the overall cohort, adverse drug events occurred in 10 (4.5%). Treatment with mAB therapy for mild to moderate COVID‐19 was associated with a substantially reduced risk of hospitalization among patients at least 65 years of age.

the available mABs therapies, bamlanivimab monotherapy and casirivimab + imdevimab, for COVID-19 resulted in lower rates of hospitalization compared to the standard of care (SOC) outside the clinical trial environment in patients age 65 years or older.

RWJBarnabas Health consists of 11 hospitals in the state of New Jersey, and is one of the largest health care systems in the state. The emergency department (ED) served as the primary setting for which the mAB agents were administered. mAB treatment was available both for patients referred from the community and for those eligible for treatment without referrals. Three large, community hospitals within RWJBarnabas Health with a high portion of usage of these agents were selected for patient capture. These hospitals were selected due to the availability of data from a consistent electronic medical record. This multi-center retrospective cohort analysis was conducted from June 1, 2020 through December 31, 2020. Since mAB therapy was not available at the study sites before November 18, 2020 all patients in the mAB treatment cohort were seen between November 18, 2020, and December 31, 2020. The trial was reviewed and approved by the local institutional review boards at all participating centers. Investigators at each site reviewed charge codes for COVID-19 diagnosis and utilized the electronic medication record to access all key clinical data findings.

Patients aged 65 years and older who presented to the ED for the first time, tested positive for SARS-CoV-2 by polymerase chain reaction or antigen test, and had one or more mild to moderate symptoms were assessed for inclusion. The COVID-19 symptoms assessed were consistent with those from the BLAZE-1 trial; patients must have reported one of the following: cough, fever, body aches/ pain, sore throat, chills, loss of taste, diarrhea, shortness of breath, fatigue, loss of appetite, headache, or loss of smell. Patients with generalized upper respiratory symptoms identified in the provider documentation were also considered symptomatic and were included. Patients were excluded if they presented with symptoms for greater than 10 days, required hospitalization on the index visit, required supplemental oxygenation, or had previously presented to the ED for COVID-19. All high-risk criteria as determined by the EUA for the mABs were evaluated. Severity of disease was assessed according to the National Institute of Health (NIH) SARS-CoV-2 infection definitions: patients without shortness of breath, dyspnea, or abnormal chest imaging classified as mild and those with shortness of breath, dyspnea, or abnormal chest imaging and not requiring supplemental oxygen were considered moderate. 1 Risk of disease progression was assessed using the CALL score. 5 The CALL score uses four variables (presence of comorbidities, age, lymphocyte count, and lactate dehydrogenase) to calculate a risk for progression to severe COVID-19. Scores range from 4 to 13, with scores from 4 to 6 having low risk for progression, 7-9 having an intermediate risk for progression, and 10-13 having a high risk for progression. For patients without laboratory assessments, values were presumed to be within normal limits.

The mAB treatment cohort included patients who met inclusion criteria and received either of the available mAB therapies during the time of the study, bamlanivmab 700 mg or casirivimab 1200 mg/imdevimab 1200 mg. SOC patients included those who met criteria for the mAB agents but did not receive them (i.e., seeking care before mAB FDA EUA, patient refusal to mAB therapy, or other undocumented reasons).

The primary outcome was hospitalization within the healthcare system for worsening COVID-19 within 30 days following index presentation to the ED. Secondary outcomes included a composite evaluation of hospitalization and ED revisits with 30 days of initial ED presentation. Additionally, intubation, hospital mortality, and treatment emergent adverse events (TEAEs) were evaluated independently. Outcomes data were collected utilizing the electronic medical record of the index hospital and five other hospitals in the health care system. Insurance claim data, ED visit, or hospitalization data external to this health system were not available.

In the overall cohort, differences in patient and treatment characteristics between patients receiving mAB versus SOC were evaluated using the Wilcoxon rank-sum test for continuous characteristics and the χ 2 or Fisher's exact test for categorical characteristics as appropriate. Due to potential confounding by indication or selection for mAB, we utilized a matched propensity score analysis to identify the odds ratio (OR) of hospitalization by mAB exposure.

The propensity model included symptom onset to ED presentation (days), severity, age, sex, temperature, BMI, and CALL score (group).

Patients were matched 1:1 from the mAB and SOC groups using a caliper of 0.2, with exact matching also performed by a specific site to control for facility-specific effects. Self-reported race or ethnicity was not included in the analysis due to inconsistent availability. Differences in patient and treatment characteristics, as well as outcomes in the matched cohort, were assessed using a conditional logistic regression model, which accounted for the matched pairs of patients.

All significance tests were two-sided with p < 0.05 considered significant. Results were reported as median (range) and N(%) where appropriate. Analyses were completed in R 4.0.2.

Across the three study sites, 675 patients found to be positive for COVID-19 during ED visit were screened and 429 patients were Of the 429 patients in the full cohort, 274 were propensity matched into 137 pairs and were included in the propensity-matched cohort. In this cohort, there were no significant differences between groups. The median symptom duration was 3 (0, 10) and 4 (1, 10) days in the SOC and mAB groups, respectively (p = 0.717). Severity of disease was mild in 62% and 59.9% of patients (p = 0.696). Median age was 71 (65, 97) and 73 (65, 100) years (p = 0.093). Median BMI was 27.9 in both groups (p = 0.346). Comorbidities, vital signs, and laboratory values were also similar between groups.

Outcomes are summarized in Table 2 Second, our study describes the use of mAB exclusively within the ED setting. The decrease in overall ED volume during the pandemic allowed for the launch of the mAB therapy in this setting with over 6000 patients treated across this New Jersey-based healthcare system. This has several important implications. Our patient population included walk-ins and provider referrals in both study groups, which may be a fundamentally different population than those seen exclusively in other outpatient settings. The ED setting also allowed collection of vital signs, as well as laboratory and radiographic data which enabled robust assessments of disease severity and prognosis.

Advantages of mAB administration in the ED include highly trained and experienced staff, 24/7 availability, and ease of access for patients. The primary disadvantage of the ED setting is throughput challenges for the patients and the department. This experience demonstrates the feasibility of the deployment of intravenous therapy for outpatients in the ED during a pandemic.

It is important to note that the mAB treatment used most frequently in these studies was bamlanivimab monotherapy. While our subgroup analysis comparing mAB therapies noted numerically lower rates of hospitalization among those receiving casirivimab + imdevimab, this study was not appropriately designed to determine optimal mAB therapy regimen. More importantly, evidence from Evidence from clinical trials indicated that mABs were largely well tolerated. We similarly found low rates of TEAEs, most of which were minor in severity. Additional questions regarding the optimal use of mAB therapy remain. This includes the timing of therapy relative to onset of symptoms. Our subgroup analysis, while underpowered, found no difference in the timing of therapy from symptom onset between those who were hospitalized and those who were not.

To our knowledge, this is the first trial to report findings of mAB treatment efficacy in a targeted high-risk subgroup, patients over 65 years, which accounts for a significant amount of usage of this agent across real-world data demographics. Our study also delineated and matched for both disease severity and risk of progression to severe COVID-19 to account for significant variables that may have influenced the outcome results. This trial did have several limitations. The accuracy of the data capture is limited by the detail provided through chart documentation. Readmission and ED revisit data may be underestimated as our data set was restricted to encounters within the healthcare system. The unbalanced timeframe for each cohort may make this study vulnerable to maturation bias. However, propensity score matching likely minimized the impact of this limitation. This analysis described the impact of patients treated within the ED. mABs have been deployed in other settings, including outpatient clinics and infusion centers, with patient populations that may differ from those presenting to the ED. Therefore, the impact of these agents in different settings may vary. Additionally, despite our propensity score matching methods, residual unmeasured confounding may exist to explain the difference in hospitalization rates that we found.

Additionally, our study timeline briefly overlapped with the initiation of vaccination efforts, primarily for healthcare workers. We did not collect COVID-19 vaccination status. While vaccination may now have an impact on efficacy and patient selection of mAB therapy, our results are unlikely to be affected. The CALL score, which we used to assess the risk of disease progression, was derived from patients in China with non-severe COVID-19 who were admitted to the hospital. This score has not been validated in the ED setting. Collectively, our findings contribute to the growing data showing the clinical benefit of these therapeutic agents for treatment of COVID-19 and help to generate increased confidence in their use in preventing COVID-19

hospitalizations.

Our retrospective propensity-matched cohort study of patients at least 65 years of age with mild to moderate COVID-19 found that those who received mAB were significantly less likely than those who did not receive therapy to require hospitalization. These findings are consistent with data from clinical trials and other real-world reports. Treatment with mAB therapy should be considered a key component of the management of mild to moderate COVID-19 among those at least 65 years old.

COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Prediction for progression risk in patients with COVID 19 pnemonia: the CALL score

Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19

Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection

Real-world experience of bamlanivimab for COVID-19: a case-control study

Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization

Division of Viral Diseases

Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults

The authors would like to acknowledge Jennifer Sternbach, PharmD for her contribution to data acquisition.

The authors declare no conflicts of interest. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0003-4847-3432Karan Raja http://orcid.org/0000-0003-0173-3313